News
Why Is Goodyear (GT) Down 17.5% Since Last Earnings Report?
It has been about a month since the last earnings report for Goodyear (GT). Shares have lost about 17.5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue
NiSource (NI) Down 2.5% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for NiSource (NI). Shares have lost about 2.5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up
Why Is Helmerich & Payne (HP) Up 7.3% Since Last Earnings Report?
A month has gone by since the last earnings report for Helmerich & Payne (HP). Shares have added about 7.3% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will
Why Is CF (CF) Down 1% Since Last Earnings Report?
It has been about a month since the last earnings report for CF Industries (CF). Shares have lost about 1% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue
Eversource (ES) Up 4.2% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Eversource Energy (ES). Shares have added about 4.2% in that time frame, outperforming the S&P 500.
Will the recent positive trend
Curtiss-Wright (CW) Up 2.6% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Curtiss-Wright (CW). Shares have added about 2.6% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue
Why Is Zillow (Z) Down 17.8% Since Last Earnings Report?
A month has gone by since the last earnings report for Zillow (Z). Shares have lost about 17.8% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to
Amneal Stock Up on FDA Nod for Romidepsin Injection Solution
Amneal Pharmaceuticals AMRX announced that the FDA has approved romidepsin injection solution (27.5 mg/5.5 mL), supplied in single-dose, ready-to-use vials for treating cutaneous T-cell lymphoma in
Jacobs Secures Major SSEN Contracts for Grid Modernization Efforts
Jacobs Solutions Inc. J has been selected by SSEN Transmission for multiple strategic frameworks to support the modernization and security of the electricity transmission network in northern
Can Chipotle Convert Rewards Growth Into Stronger Traffic?
Chipotle Mexican Grill, Inc. CMG is sharpening its loyalty strategy as it looks to convert stronger guest engagement into repeat traffic. The company’s refreshed Rewards program is designed to widen
2 Funds to Buy as Manufacturing Activity Roars Back to 4-Year High
The U.S. manufacturing sector is showing solid signs of recovery after facing challenges for months. Despite rising supply constraints in recent weeks, manufacturing activity accelerated in May
Top Robotics Stocks Worth Investing in the Second Half of 2026
An updated edition of the April 16, 2026, article. The American robotics industry has entered a decisive acceleration phase in 2026, with recent months emerging as a landmark across physical AI
A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
Key Points
- Interested in lululemon athletica inc.? Here are five stocks we like better.
- Lululemon's Q1 revenue of $2.47 billion beat a lowered consensus, but weak guidance and U.S. market
MSTR's Liquidity Position Improves: Is Long-Term Stability Growing?
Strategy Inc.’s MSTR improving liquidity profile and strengthening balance sheet durability are reinforcing confidence in its long-term stability despite continued volatility in the bitcoin market
Buy 5 Stocks With High ROE as Markets Swing on War Skirmishes
The broader equity markets witnessed intense volatility over the past week, hitting record highs on one hand and plummeting sharply on the other, as skirmishes in the Iran-U.S. war continued with a
Is RCL Turning the Corner on Mediterranean Booking Weakness?
Royal Caribbean Cruises Ltd. RCL is seeing early improvement in Mediterranean booking trends — a key part of its high-yielding European itinerary portfolio — after geopolitical disruption pressured
MRVL Surges 363% in a Year: Time to Buy, Sell or Hold the Stock?
Marvell Technology MRVL shares have skyrocketed 363% in the past year, outperforming the Zacks Electronics - Semiconductors industry and Zacks Computer and Technology sector’s return of 129.5% and
Data Center Power Demands Push This Dividend Aristocrat to All Time Highs
Caterpillar CAT shares continue to deliver a stellar performance in 2026, up more than 60% and widely outperforming the S&P 500. The stock represents a clear favorite for gaining exposure to the
4 Best Low-Beta Stocks to Buy Right Away: LQDA, CVX, OXY & VLO
Escalating tensions in the Middle East, as reflected in the Iran war, are now in a fragile ceasefire, creating significant uncertainty and making the U.S. stock market highly volatile. With fears
Nonfarm Payrolls Increased More Than Expected
Ahead of the final trading session of the week, pre-market futures are tightening a bit as investors digest the latest Employment Situation report from the U.S. Bureau of Labor Statistics (BLS) for
VZ Shares Rise 8.6% in Six Months: What's the Next Move for Investors?
Verizon Communications Inc. VZ has gained 8.6% in six months against the Wireless National industry’s decline of 3.8%. The stock has underperformed the Zacks Computer & Technology sector during this
Synopsys' AI Strategy: Is it a Key Driver of Future Expansion?
Synopsys SNPS is gaining from a multi-trillion-dollar AI infrastructure buildout, driving strong system-level and semiconductor R&D spending and robust AI compute design activity. Synopsys is
Mama's Creations Q1 Earnings Awaited: Key Insights for Investors
Mama's Creations, Inc. MAMA is likely to witness top-line growth when it reports first-quarter fiscal 2027 earnings on June 8, 2026. The Zacks Consensus Estimate for revenues is pegged at $51.8
AVGO Shares Drop 13% Post Q2 Results: Buy, Sell or Hold on the Dip?
Broadcom AVGO shares dropped a massive 12.6% following its second-quarter fiscal 2026 results despite reporting strong revenue (beat the Zacks Consensus Estimate by 0.68%) and earnings (beat the



